On the Halozyme call I didn't get they were real close to a partnership but I commented on the Halo board a few days ago that I got the sense they were seeking more a generic company to partner with #msg-68652072 I only listened once so far but pretty sure there was one remark that made mention of generic company would need more time/info to get a comfort level. So that would be my guess right now.
Part of how Frost answers needs to be taken in context too. Lim was talking partnering for a couple years I believe so the company doesn't have a lot of creditability here so Frost isn't in the best of situations to talk about a deal coming "soon".
On the array data. I am not that familiar with the patient population to speculate. It would seem to me that the better potential would be combination use and already AE's are fairly high in monotherapy.
Market Data 
Markets 
AI
